|
Sign In to gain access to subscriptions and/or personal tools.
|
Utilising cardiopulmonary bypass for cancer surgery. Malignancy-induced protein C deficiency and thrombophilia
C Marshall
Cardiac Surgery Theatres, Perfusion Office, Cork University Hospital, Wilton, Cork, Ireland
Cardiopulmonary bypass has evolved over the last 30 years. It is an important tool for the cardiac surgeon today and also has applications in non-cardiac operations such as surgery to extract tumours. Such patients undergoing surgery for cancer may be at an increased risk of a thromboembolic event post surgery, due to disturbances in the normal clotting pathway leading to hypercoagulability. One such disturbance is malignancy-induced Protein C deficiency. A deficiency of Protein C can cause hypercoagulabitity. Recent studies have examined cardiopulmonary bypass and inherited Protein C deficiency. However, surgery for cancer patients with a malignancy-induced Protein C deficiency involving cardiopulmonary bypass has not been reported. Surgery using CPB in these patients may result in increased morbidity and mortality. The objective of this article is to review the literature in order to discuss the occurrence, the aetiology and possible management of cancer patients with malignancy-induced Protein C deficiencies that require cardiopulmonary bypass for their surgery.
References
- 1 Edmunds LH . The evolution of cardiopulmonary bypass: lessons to be learned. Perfusion 2002; 17 : 243 – 251 . [Abstract/Free Full Text]
- 2 Nair KSLawrence DRPunjabi PP . Indications for cardiopulmonary bypass in non-cardiac operations. Perfusion 2002; 17 : 161 – 166 . [Free Full Text]
- 3 Ridley PDLedingham SJLennox SC . Protein C deficiency associated with massive cerebral thrombosis following open heart surgery. Cardiovascular Surgery 1990; 31 ( 2 ): 249 – 251 .
- 4 Van’t Veer CGolden NJKalafatis MMann KG . Inhibitory mechanism of the Protein C pathway on tissue factor-induced thrombin generation. J Biol Chem 1997; 272 ( 12 ): 7983 – 7994 . [Abstract/Free Full Text]
- 5 Jandl HJ . Blood. USA : Little Brown Company; 1987 . p. 965 – 969 .
- 6 Sievert AMcCall MBlackwell M . Use of aprotinin during cardiopulmonary bypass in a patient with Protein C deficiency. J Extra Corpor Technol 2003; 35 : 39 – 45 . [Medline]
[Order article via Infotrieve]
- 7 Bronze GJMiletick JP . Hemostasia and Thrombosis. In: Colman, Hirish, Marden, Salzman, (eds), Hemostasia and thrombosis, basic principles and clinical practice, third edition. Lippincott company; 1993 . p. 262.
- 8 Debois WLiu JLee L . Cardiopulmonary bypass in patients with pre-existing coagulopathy. J Extra Corpor Technol 2005; 37 : 15 – 22 . [Medline]
[Order article via Infotrieve]
- 9 Greaves MPreston FE . Pathogenesis of thrombosis antithrombotic therapy. In: Hoffbrand, AV, Lewis, SM, Tuddenham, (eds), Postgraduate Haematology, fourth edition. London: Arnold; 2001 . p. 659.
- 10 Mannucci PMGiangrande PLF . Acquired disorders of coagulation. In: AL BloomDF ForbesPT ThomasEG Tuddenham , (eds), Haemostasis and Thrombosis , Third edition . Singapore : Churchill Livingstone; 1994 . p. 955 .
- 11 Derhaschnig UReiter RKnobl K . Recombinant human activated protein C (rhAPC; detrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood 2003; 102 : 2093 – 2098 . [Abstract/Free Full Text]
- 12 Tanaka TA; Szlam F; Levy JH;. The effect of aprotinin on activated protein c-mediated downregulation of endogenous thrombin generation. Br haemotol 2006; 134: 77–82.
Perfusion, Vol. 22, No. 6,
381-383 (2007)
DOI: 10.1177/0267659108089138
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
